Emily Field
Stock Analyst at Barclays
(3.15)
# 2,565
Out of 5,004 analysts
719
Total ratings
45.8%
Success rate
2%
Average return
Main Sectors:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintained: Buy | $1,400 | $1,183.46 | +18.30% | 31 | Sep 28, 2026 | |
| AMGN Amgen | Reiterated: Hold | $380 | $414.61 | -8.35% | 9 | Sep 17, 2026 | |
| MRK Merck & Co. | Reiterated: Hold | $150 → $171 | $148.78 | +14.69% | 13 | Sep 7, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $110 | $64.66 | +70.12% | 9 | Aug 26, 2026 | |
| GILD Gilead Sciences | Reiterated: Hold | $145 | $150.93 | -3.93% | 5 | Aug 13, 2026 | |
| PFE Pfizer | Reiterated: Sell | $25 | $28.67 | -12.80% | 6 | Aug 13, 2026 | |
| BIIB Biogen | Reiterated: Hold | $200 | $227.60 | -12.13% | 7 | Aug 12, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $300 | $264.34 | +13.49% | 11 | Aug 11, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 | $62.86 | +19.31% | 8 | Aug 11, 2026 | |
| GSK GSK plc | Downgraded: Sell | n/a | $49.24 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $145.46 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $54.45 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $41.11 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 275.00 | CHF 360.30 | n/a | 59 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €115.00 → €105.00 | €71.79 | n/a | 37 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 1,450p | 1,851p | n/a | 126 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 46.50 → CHF 55.00 | CHF 71.16 | n/a | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 14,000p | 12,552p | n/a | 78 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €22.00 | €25.98 | n/a | 32 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | CHF 90.00 | CHF 119.80 | n/a | 44 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €25.00 | €50.02 | n/a | 59 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 2,000p | 1,590p | n/a | 61 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €195.00 | €135.00 | n/a | 74 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €8.00 → €9.00 | €9.59 | n/a | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €75.00 | €143.30 | n/a | 22 | Nov 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $142 → $125 | $29.38 | n/a | 7 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $51.96 | $22.10 | n/a | 1 | Aug 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $0.00001 | n/a | 1 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $7.34 | n/a | 2 | Jun 1, 2018 |
Eli Lilly and Company
Sep 28, 2026
Maintained: Buy
Price Target: $1,400
Current: $1,183.46
Upside: +18.30%
Amgen
Sep 17, 2026
Reiterated: Hold
Price Target: $380
Current: $414.61
Upside: -8.35%
Merck & Co.
Sep 7, 2026
Reiterated: Hold
Price Target: $150 → $171
Current: $148.78
Upside: +14.69%
Cytokinetics
Aug 26, 2026
Reiterated: Buy
Price Target: $110
Current: $64.66
Upside: +70.12%
Gilead Sciences
Aug 13, 2026
Reiterated: Hold
Price Target: $145
Current: $150.93
Upside: -3.93%
Pfizer
Aug 13, 2026
Reiterated: Sell
Price Target: $25
Current: $28.67
Upside: -12.80%
Biogen
Aug 12, 2026
Reiterated: Hold
Price Target: $200
Current: $227.60
Upside: -12.13%
AbbVie
Aug 11, 2026
Reiterated: Buy
Price Target: $300
Current: $264.34
Upside: +13.49%
Bristol-Myers Squibb Company
Aug 11, 2026
Reiterated: Buy
Price Target: $75
Current: $62.86
Upside: +19.31%
GSK plc
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $49.24
Upside: -
Jan 6, 2026
Upgraded: Hold
Price Target: n/a
Current: $145.46
Upside: -
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $54.45
Upside: -
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $41.11
Upside: -
Sep 24, 2025
Reiterated: Hold
Price Target: CHF 275.00
Current: CHF 360.30
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: €115.00 → €105.00
Current: €71.79
Upside: n/a
Aug 12, 2025
Reiterated: Hold
Price Target: 1,450p
Current: 1,851p
Upside: n/a
Aug 8, 2025
Reiterated: Buy
Price Target: CHF 46.50 → CHF 55.00
Current: CHF 71.16
Upside: n/a
Jul 30, 2025
Reiterated: Buy
Price Target: 14,000p
Current: 12,552p
Upside: n/a
Jul 29, 2025
Reiterated: Sell
Price Target: €22.00
Current: €25.98
Upside: n/a
Jul 21, 2025
Reiterated: Sell
Price Target: CHF 90.00
Current: CHF 119.80
Upside: n/a
Jun 27, 2025
Reiterated: Hold
Price Target: €25.00
Current: €50.02
Upside: n/a
Apr 25, 2025
Reiterated: Hold
Price Target: 2,000p
Current: 1,590p
Upside: n/a
Oct 29, 2024
Reiterated: Buy
Price Target: €195.00
Current: €135.00
Upside: n/a
Nov 21, 2022
Reiterated: Sell
Price Target: €8.00 → €9.00
Current: €9.59
Upside: n/a
Nov 25, 2021
Reiterated: Sell
Price Target: €75.00
Current: €143.30
Upside: n/a
Jan 19, 2021
Reiterated: Hold
Price Target: $142 → $125
Current: $29.38
Upside: n/a
Aug 28, 2020
Reiterated: Hold
Price Target: $51.96
Current: $22.10
Upside: n/a
Apr 25, 2019
Reiterated: Buy
Price Target: $14
Current: $0.00001
Upside: n/a
Jun 1, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $7.34
Upside: n/a